This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic lung disease (CLD) of prematurity has emerged as the most common, lethal and expensive remaining neonatal pulmonary disorder in the United States. The estimated prevalence is 10,000-15,000 cases in the nation. Current therapeutic approaches to prevention and treatment of lung disease of infants, which include antenatal corticosteroid treatment, surfactant replacement, and postnatal administration of steroids, Viatmin A, diuretics and bronchodilators, have not resulted in clinically significant decreases in CLD. Infants with the most severe forms of CLD develop increased airway resistance and findings consistent with pulmonary hypertension with cor pulmonale.
Showing the most recent 10 out of 463 publications
